Ra Pharmctl Inc (NASDAQ:RARX) issued its earnings results on Wednesday. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.06, Bloomberg Earnings reports.

Shares of Ra Pharmctl (NASDAQ RARX) traded down 0.52% during trading on Thursday, reaching $13.52. 143,615 shares of the company’s stock were exchanged. Ra Pharmctl has a 12-month low of $12.05 and a 12-month high of $27.84. The company has a 50 day moving average of $16.56 and a 200 day moving average of $20.33. The stock’s market cap is $305.11 million.

RARX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Ra Pharmctl from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Jefferies Group LLC restated a “buy” rating and issued a $25.00 target price on shares of Ra Pharmctl in a research note on Wednesday, April 26th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $19.00 target price on shares of Ra Pharmctl in a research note on Tuesday, April 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Ra Pharmctl has an average rating of “Buy” and a consensus price target of $27.00.

COPYRIGHT VIOLATION NOTICE: “Ra Pharmctl Inc (NASDAQ:RARX) Issues Earnings Results” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/ra-pharmctl-inc-nasdaqrarx-issues-earnings-results/1471416.html.

In other news, major shareholder Bioventures Ltd Novartis sold 9,019 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $25.50, for a total value of $229,984.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 208,880 shares of company stock worth $4,946,431 over the last three months. Insiders own 14.50% of the company’s stock.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.